Abivax SA American Depositary Shares (ABVX) Stock
NASDAQ · ABVX
95.45
Fundamentals
Market cap
$7.95B
Price / Earnings ratio
-16.4x
Price / Sales ratio
1316.7x
Price / Book ratio
18.1x
Return on assets
-70.0%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.00%
Debt / Equity ratio
N/A
Recent news

Zacks Investment Research
4 Biotech Stocks to Watch as Potential Takeover Targets
NeutralABVXSeptember 18, 2026
Zacks Investment ResearchNeutral
4 Biotech Stocks to Watch as Potential Takeover Targets
ABVX

Zacks Investment Research
Abivax SA Sponsored ADR (ABVX) Upgraded to Buy: Here's Why
NeutralABVXSeptember 8, 2026
Zacks Investment ResearchNeutral
Abivax SA Sponsored ADR (ABVX) Upgraded to Buy: Here's Why
ABVX

Zacks Investment Research
Should You Buy Abivax SA Sponsored ADR (ABVX) After Golden Cross?
NeutralABVXJuly 10, 2026
Zacks Investment ResearchNeutral
Should You Buy Abivax SA Sponsored ADR (ABVX) After Golden Cross?
ABVX

CNBC
Abivax $920 million cash haul lets it prepare for solo U.S. launch instead of relying on a buyer, CEO tells CNBC
NeutralABVXJuly 10, 2026
CNBCNeutral
Abivax $920 million cash haul lets it prepare for solo U.S. launch instead of relying on a buyer, CEO tells CNBC
ABVX
Technicals
OscillatorsSell5 Indicators
Moving AveragesStrong Sell12 Indicators
Analyst Ratings
Strong Sell0
Sell0
Neutral1
Buy8
Strong Buy0
Financials
Performance
Revenue
Net income
Net margin %
2025
6M4M2M0
Debt & Balance Sheet
Total assets
Total liabilities
2025
701M463M231M0
Revenue to Profit
2025$5.4M
Revenue$0.0
Cost of revenue$0.0
Gross profit$0.0
Operating expenses$-336.1M
Net incomeEarnings
No data available
% positive news of 10 articles
published over the past 14 days
Latest news

Zacks Investment Research
4 Biotech Stocks to Watch as Potential Takeover Targets
NeutralABVXSeptember 18, 2026
Zacks Investment ResearchNeutral
4 Biotech Stocks to Watch as Potential Takeover Targets
ABVX

Zacks Investment Research
Abivax SA Sponsored ADR (ABVX) Upgraded to Buy: Here's Why
NeutralABVXSeptember 8, 2026
Zacks Investment ResearchNeutral
Abivax SA Sponsored ADR (ABVX) Upgraded to Buy: Here's Why
ABVX

Zacks Investment Research
Should You Buy Abivax SA Sponsored ADR (ABVX) After Golden Cross?
NeutralABVXJuly 10, 2026
Zacks Investment ResearchNeutral
Should You Buy Abivax SA Sponsored ADR (ABVX) After Golden Cross?
ABVX

CNBC
Abivax $920 million cash haul lets it prepare for solo U.S. launch instead of relying on a buyer, CEO tells CNBC
NeutralABVXJuly 10, 2026
CNBCNeutral
Abivax $920 million cash haul lets it prepare for solo U.S. launch instead of relying on a buyer, CEO tells CNBC
ABVX

MarketBeat
Abivax: Wall Street Catches Up to the Data
NeutralABVXJuly 7, 2026
MarketBeatNeutral
Abivax: Wall Street Catches Up to the Data
ABVX

Stocktwits
ABVX Stock Eyes Over Six-Month High As Investors Double Down On Abivax's Lead Drug Bet – Buyout Chatter Builds
NeutralABVXJuly 2, 2026
StocktwitsNeutral
ABVX Stock Eyes Over Six-Month High As Investors Double Down On Abivax's Lead Drug Bet – Buyout Chatter Builds
ABVX

Reuters
Abivax nears $11 billion valuation after fundraising eases M&A pressure
NeutralABVXJuly 1, 2026
ReutersNeutral
Abivax nears $11 billion valuation after fundraising eases M&A pressure
ABVX

Stocktwits
ABVX Stock Clocks Best Day In 11 Months On Analyst Upgrades After Fresh Data Eases Drug Safety Concerns
NeutralABVXJuly 1, 2026
StocktwitsNeutral
ABVX Stock Clocks Best Day In 11 Months On Analyst Upgrades After Fresh Data Eases Drug Safety Concerns
ABVX

Proactive Investors
Abivax shares jump as updated trial data eases safety concerns
NeutralABVXJune 30, 2026
Proactive InvestorsNeutral
Abivax shares jump as updated trial data eases safety concerns
ABVX

CNBC
French biotech stock soars 25% after new data on experimental medicine
NeutralABVXJune 30, 2026
CNBCNeutral
French biotech stock soars 25% after new data on experimental medicine
ABVX
About Abivax SA American Depositary Shares
No description available.
SectorHealthcare
IndustryBiotechnology
Employees98
CEOMr. Marc M. P. de Garidel M.B.A.
IPO DateOct 20, 2023
HeadquartersParis, France
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Marc M. P. de Garidel M.B.A. | CEO & Director | 1958 |
| Mr. Didier Blondel | EVP, CFO & Board Secretary | 1964 |
| Dr. David Zhang Ph.D. | Chief Strategy Officer | 1968 |
| Dr. Keith M. Fournier Ph.D. | Senior Vice President of Global Regulatory Affairs | — |
| Mr. Michael Nesrallah M.B.A. | Chief Commercial Officer | — |
| Dr. Maurus de la Rosa Ph.D. | Senior Vice President of Research | — |
| Mr. Ivan Nunez-Pacheco | Global Head of Patient Services | — |
| Ms. Heather Dean | Global Head of Sales, Accounts & Commercial Operations | — |
| Mr. Jeffrey N. Haas | Global Head of Market Access & Pricing | — |
Fundamentals
Valuation
Market cap$7.95B
Price-to-sales ratio1,316.73
Price-to-book value18.07
Price-earnings ratio-16.40
Return on Equity-99.00%
Return on Sales-4342.00%
Return on Assets-70.00%
PEG ratioN/A
Earnings Per Share
Earnings Per Share$-5.94
Income Statement
Average volume1,252,465
EBITDA$-242.53M
1 year high (52w)$148.83
1 year low (52w)$69.81
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A
Technicals
OscillatorsSell5 Indicators
Moving AveragesStrong Sell12 Indicators
What the experts say
9 Wall Street Analyst Ratings
BUY
89% Buy
11% Hold
0% Sell
Target price
$157.22
Est return
71.27%
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023 | +10.8 | +4.0 | +6.3 | |||||||||
| 2024 | +22.0 | +3.3 | +2.6 | +7.4 | -6.9 | -1.9 | -12.9 | +8.1 | -7.2 | -5.9 | -16.9 | -13.7 |
| 2025 | -18.1 | +29.3 | -14.7 | +20.9 | -12.9 | +20.5 | +836.9 | +12.6 | +3.5 | +24.3 | +26.3 | +12.5 |
| 2026 | -16.9 | +8.8 | -1.6 | +2.1 | +12.8 | +2.8 | -5.8 | -10.5 | -19.9 |



